A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 44
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MTAs
Long Form : molecularly targeted agents
No. Year Title Co-occurring Abbreviation
2020 A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients. ASCO, HRs, mOGC, OS, PFS
2019 Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose. MTD, PI
2019 Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. ESMO, MAs, OS, PFS
2018 Biomarker enrichment considerations in oncology early development single-arm studies. POC
2018 Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents. AEs, CCs
2018 Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. FAEs, HCC, PRISMA, RCTs
2018 Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer: Does the age matter? CIs, HR, mCRC, OS, PFS, RCTs
2018 Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome. FACT, VUS
2017 Determinants of the recommended phase 2 dose of molecular targeted agents. FDA, RP2D
10  2017 Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. HCC, OS, PFS
11  2017 Dose-finding designs for trials of molecularly targeted agents and immunotherapies. ---
12  2017 Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground? BTCs, ECCs, FGFR2, GBCs, ICCs, SWI/SNF
13  2017 Molecularly targeted agents in oculoplastic surgery. ---
14  2017 Optimal sequential enrichment designs for phase II clinical trials. OSE
15  2017 Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. ABTC
16  2017 Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. PFS, PFSMTA, PFSTPC, TPC
17  2017 Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. DLTs, ITCC
18  2017 Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis. AEs, FAEs, GC, RCTs
19  2016 An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. ---
20  2016 Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. AEs, CTEP
21  2016 Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials. DLTs
22  2016 Combination treatment including targeted therapy for advanced hepatocellular carcinoma. HCC
23  2016 Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis. BTC, ORR, OS, PFS, RCTs, RR
24  2016 Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter? CI, HR, mCRC, OS, PFS
25  2016 The changing landscape of phase I trials in oncology. ---
26  2016 Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. ---
27  2015 Design and statistical principles of the SHIVA trial. ---
28  2015 Early phase clinical trials to identify optimal dosing and safety. ---
29  2015 Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. CI, CRPC, HR, ORRs, OS, PFS, RCTs, RR, RR, RR
30  2015 Withdrawal of anticancer therapy in advanced disease: a systematic literature review. KIs
31  2014 Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice. EP, IFN, LAN, mTOR, NETs, OCT, PAS, PNETs, SSAs, SSTR, WD, MD
32  2014 Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. OAEs
33  2014 Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. CI, EGFR, GEM, RRs
34  2014 Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. DLT, EORTC, RDI
35  2013 A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. BSA, RPIID
36  2013 Safety and feasibility of targeted agent combinations in solid tumours. ---
37  2012 Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. BED, MTD
38  2012 Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. CI, HR, ORRs, OS, PC, PFS, RCTs
39  2012 Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. MTD
40  2012 Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. TGr
41  2011 Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? ---
42  2011 Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. mRCC, RI
43  2009 Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? MTD, NPR
44  2008 Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. LDH, SAE, SAE